摘要
目的:对比分析左乙拉西坦和托吡酯治疗癫痫的效果和安全性。方法:选取2020年1月-2021年1月解放军联勤保障部队第九〇四医院常州院区收治的癫痫患者60例为观察对象。采用双盲对照原则分为观察组与对照组,各30例。对照组给予托吡酯治疗,观察组给予左乙拉西坦治疗。比较两组患者治疗总有效率、不良反应发生率。结果:观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05);两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:在癫痫患者治疗过程中左乙拉西坦和托吡酯均有着较为理想的表现,安全性较高,左乙拉西坦的治疗效果优于托吡酯。
Objective:To compare and analyze the efficacy and safety of levetiracetam and topiramate in the treatment of epilepsy.Methods:Sixty epilepsy patients admitted to Changzhou Campus,No.904 Hospital of PLA Joint Logistic Service Support Force from January 2020 to January 2021 were selected as the observation subjects,and they were divided into control group and observation group according to double-blind control principle,with 30 cases in each group.The control group was treated with topiramate and the observation group was treated with levetiracetam.The total effective rate of treatment and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of treatment in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05);there was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Both levetiracetam and topiramate have ideal performance and high safety in the treatment of epilepsy patients,and the treatment effect of levetiracetam is better than that of topiramate.
作者
蒋建波
廖振阳
陈升东
Jiang Jian-bo;Liao Zhen-yang;Chen Sheng-dong(Department of Neurology,Changzhou Campus,No.904 Hospital of PLA Joint Logistic Service Support Force,Changzhou 213000,Jiangsu Province,China)
出处
《中外医药研究》
2022年第5期27-29,共3页
JOURNAL OF CHINESE AND FOREIGN MEDICINE AND PHARMACY RESEARCH
关键词
癫痫
托吡酯
左乙拉西坦
不良反应
Epilepsy
Topiramate
Levetiracetam
Adverse reaction
